Cognition Therapeutics (CGTX) Gains from Sales and Divestitures (2024 - 2026)
Cognition Therapeutics (CGTX) reported Gains from Sales and Divestitures of $551892.0 for Q1 2026, up 197.31% year-over-year from $185626.0 in Q1 2025, and down 35.93% on a QoQ basis from $861403.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 3 years of Gains from Sales and Divestitures data on file, last reported at $551892.0 in Q1 2026.
- Quarterly Gains from Sales and Divestitures rose 197.31% year-over-year to $551892.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $551892.0 (up 197.31% YoY) and the FY2025 annual result came in at $861403.0, up 369.48% from the prior year.
- Gains from Sales and Divestitures fell to $551892.0 in Q1 2026 per CGTX's latest filing, from $861403.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $861403.0 in Q4 2025 and bottomed at $118527.0 in Q1 2024.
- The 3-year median for Gains from Sales and Divestitures is $185626.0 (2025), against an average of $352431.0.
- Peak annual rise in Gains from Sales and Divestitures reached 369.48% in 2025, while the deepest fall reached 43.62% in 2025.
- Tracing CGTX's Gains from Sales and Divestitures over 3 years: stood at $183482.0 in 2024, then soared by 369.48% to $861403.0 in 2025, then plunged by 35.93% to $551892.0 in 2026.
- Per Business Quant, the three latest CGTX Gains from Sales and Divestitures figures stand at $551892.0 (Q1 2026), $861403.0 (Q4 2025), and $642903.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 551,892.00 |
| Mar 31, 2026 | 551,892.00 |
| Dec 31, 2025 | 861,403.00 |
| Dec 31, 2025 | 861,403.00 |
| Sep 30, 2025 | 642,903.00 |
| Sep 30, 2025 | 642,903.00 |
| Jun 30, 2025 | 262,082.00 |
| Jun 30, 2025 | 262,082.00 |
| Mar 31, 2025 | 185,626.00 |
| Mar 31, 2025 | 185,626.00 |
| Dec 31, 2024 | 183,482.00 |
| Dec 31, 2024 | 183,482.00 |
| Sep 30, 2024 | 183,482.00 |
| Sep 30, 2024 | 183,482.00 |
| Jun 30, 2024 | 182,482.00 |
| Jun 30, 2024 | 182,482.00 |
| Mar 31, 2024 | 118,527.00 |
| Mar 31, 2024 | 118,527.00 |